">
Tuesday, 5 May 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 05 May 2026
News

Lilly GM confirms drug launch

Posted 5 May 2026 AM

Acknowledging the “significant challenges” of securing subsidy for innovative medicines in Australia, Eli Lilly Australia General Manager, Manny Simons, has announced its blood cancer drug Jaypirca will be launched on private script soon.

Jaypirca became the first and only non-covalent (reversible) BTK inhibitor approved for use in Australia in March. It is indicated for the treatment of adults with relapsed and refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), who have previously been treated with a covalent BTK inhibitor.

To see the whole article, please login

Popular

Who's made a move to new digs?
Who's won an MA Board seat?
Aussie pharma on the nose
Aussie discovery goes commercial
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home